Flu Trial Failure

Vir Biotech's Stock Soars and Plummets: A Rollercoaster Ride in the Pandemic

Shares of Vir Biotechnology plunged 43% after the company's trial for an influenza prophylaxis failed, causing the stock to drop to around $13.